相关实验视频
Updated: May 30, 2025

05:14
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
4.4K
人类环素诱导的心肌病:风险预测,预防和治疗
Iacopo Fabiani1, Michela Chianca2, Carlo Maria Cipolla3
1Cardiology Division, Fondazione Toscana Gabriele Monasterio, Pisa, Italy. iacopofabiani@gmail.com.
Nature reviews. Cardiology
|January 28, 2025
概括
人环素心脏毒性对癌症患者的生存和生活质量构成重大威胁. 早期风险分层和及时治疗对于管理这种独特的心肌病症至关重要.
科学领域:
- 在瘤学瘤学.
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 人环素在癌症治疗中至关重要,但引起显著的心脏毒性.
- 这种心脏毒性会降低患者的生存率和生活质量,无论癌症的预后如何.
- 了解环素诱导的心肌病变对于患者管理至关重要.
研究的目的:
- 为了提供一个全面的临床综述的anthracycline心脏毒性.
- 涵盖流行病学,机制,风险因素,诊断和治疗策略.
- 讨论心力衰竭的新型心脏保护剂.
主要方法:
- 综述当前关于antracycline心脏毒性的文献.
- 综合有关风险分层,诊断工具 (成像,生物标志物) 和治疗指南的信息.
- 探索新兴的心脏保护疗法.
主要成果:
- 环素心脏毒性是一个渐进的过程,从心肌损伤到心力衰竭.
- 早期检测和干预是减轻不良影响的关键.
- 使用成像和生物标志物的风险分层有助于识别易感患者.
结论:
- 为了有效地管理环素心脏毒性,需要采用多方面的方法.
- 早期识别有风险的患者和及时干预至关重要.
- 新型心脏保护策略在治疗心脏衰竭的第二次治疗中充满希望.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
375
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
375
Heart Failure Drugs: Inotropic Agents
507
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
507
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Ischemic Heart Disease: Overview
1.2K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.2K
Cardiovascular Drugs: Classification based on Therapeutic Indications
2.0K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.0K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
131
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
131

